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Patterns of hepatitis B prevalence and seroconversion in hemo- Hepatitis B virus (HBV) historically has been a critical
dialysis units from three continents: The DOPPS. infection issue within hemodialysis facilities. [1, 2] Con-
Background. Hepatitis B (HBV) historically has been a pub- siderable transmission of HBV can occur between hemo-
lic health issue within hemodialysis units. This study estimates
dialysis patients and staff [3]. Hemodialysis patients areHBV prevalence and seroconversion rates across seven coun-
at increased risk for HBV infection because of the oppor-tries and investigates associations with facility level practice
tunity for exposure to HBV associated with the dialysispatterns.
Methods. The study sample was from the Dialysis Outcomes procedure. The reservoir of infection for potential trans-
and Practice Patterns Study (DOPPS), a cross-sectional, pro- mission of HBV is greater in hemodialysis patients. After
spective, observational study of adult hemodialysis patients infection with HBV, hemodialysis patients are at greater
randomly selected from 308 dialysis facilities in France, Ger-
risk of becoming chronic carriers than the general popula-many, Italy, Spain, the United Kingdom, Japan, and the United
tion [3–5]. Moreover, the conversion rate after vaccinationStates. Logistic regression was used to model the odds ratio
(OR) of HBV prevalence, and Cox regression was used to is less for chronic hemodialysis patients than for the gen-
model time from entry into the study to HBV seroconversion. eral population (50% to 80% vs.95%) [6–10]. Although
Results. In this sample, mean HBV facility prevalence was many patients with end-stage renal disease (ESRD) do
3.0% with a median of 1.9%. The percentage of facilities with not live long enough to develop HBV-related complica-an HBV prevalence 0% to 5% was 78.5%. Adjusted HBV
tions, increased risk of hepatocellular carcinoma andprevalence was higher in France, Germany, and Italy and lower
mortality associated with HBV is reported in the ESRDin Japan and the United Kingdom. The majority of facilities
(78.1%) had a seroconversion rate of 0 conversions per 100 population [11–13]. HBV infection is also associated with
patient-years. Presence of a protocol for HBV-infected patients greater morbidity and mortality in ESRD patients after
was significantly associated with HBV seroconversion in the they have received a renal transplant [14–20].
separate practice pattern model [risk ratio (RR)  0.52, P  The hemodialysis and infectious disease communities0.03] and in the combined practice pattern model (RR  0.44,
have developed practice patterns and infection controlP  0.01).
measures designed to reduce HBV transmission. TheseConclusion. There are differences in HBV prevalence and
rate of seroconversion both at the country and the hemodialysis include protocols for handling bodily fluids, isolation
facility level. Presence of a protocol for HBV-infected patients policies, the HBV vaccine, and use of erythropoietin
was strongly and significantly associated with decreased risk for [21–27]. However, HBV persists within hemodialysis
seroconversion. The observed variation suggests opportunities units. Furthermore, there is observed variation in HBV
for improved HBV outcomes with further definition of optimal
prevalence and seroconversion between hemodialysispractice patterns at the facility level.
units. It is likely that facility-level practice patterns affect
HBV transmission, even in the current environment of
infection control measures.Key words: hepatitis B, infection control protocols, Dialysis Outcomes
and Practice Patterns Study, seroconversion, vaccine. Several country- and region-specific studies have
looked at HBV prevalence and seroconversion in hemo-Received for publication October 16, 2002
dialysis units [10, 23, 25, 26, 28–32]. Worldwide, uni-and in revised form December 20, 2002
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present study used data from the Dialysis Outcomes cardiac disease other than CHF, hypertension, diabetes,
and Practice Patterns Study (DOPPS) to estimate HBV cerebrovascular disease, peripheral vascular disease
prevalence and seroconversion rates in seven countries (PVD), cancer, human immunodeficiency virus/acquired
and to investigate whether facility-level practice patterns immunodeficiency syndrome (HIV/AIDS), lung disease,
were associated with HBV prevalence and seroconver- neurologic disorders, psychiatric disease, and gastroin-
sion. The standardization of DOPPS data collection testinal bleed. Confidence intervals for unadjusted and
allows for direct comparison of HBV across hemodialysis adjusted prevalence and seroconversion measures of as-
facilities and across countries at a level of detail and sociation were constructed for each country.
power that has not previously been reported. Practice pattern analysis. Associations among facility
practice patterns and the facility prevalence of HBV
infection were examined using logistic regression. Asso-METHODS
ciations among facility practice patterns and time toData sources
HBV seroconversion were examined using Cox propor-
This study used a sample of 8615 hemodialysis patients tional hazards models. Practice patterns modeled as pre-
from the DOPPS, a cross-sectional, prospective, observa- dictor variables included the following facility character-
tional study involving a sample of adult hemodialysis
istics: protocol for HBV-infected patients, isolation of
patients randomly selected from 308 representative dial-
HBV-infected patients, isolation of HCV-infected pa-ysis facilities in France, Germany, Italy, Spain, the
tients, number of isolation stations (per station), patientsUnited Kingdom, Japan, and the United States. Facilities
per station (per one-unit increase), routine administra-in the United States entered the study in 1997, Europe in
tion of HBV vaccine, number of highly trained staff (per1998, and Japan in 1999. This analysis used data gathered
10% increase in highly trained staff), physician-patientthrough spring 2001. Nationally representative samples
interaction (hours/month), ratio of patient hours to di-were obtained using randomized patient selection, with
rect patient staff hours, routine serologic screening forongoing longitudinal patient and facility data collection.
HBV, routine serologic screening for HCV, facility size,The DOPPS sampling plan and study methods have been
dialyzer reuse, and whether the hemodialysis facilitydescribed elsewhere [33].
treated acute patients. Highly trained staff members
Classification of HBV status were defined as those who had received at least 2 years
of formal nursing training. These models were also ad-Answers to the question, “Diagnosis of hepatitis B on
justed for the demographic characteristics and comorbid-or before the enrollment date? Yes/No/Suspected,” were
combined with serology results to define HBV classifica- ities listed above, as well as time since beginning of
tion. Patients were considered to have a clinical diagnosis ESRD.
of HBV if they answered “yes” to the above question. All models accounted for clustering at the facility level.
A case of HBV was defined as a patient who carried a For the logistic regression models, generalized estimat-
clinical diagnosis of HBV or who was HBV surface anti- ing equations (GEE) were used to account for clustering
gen (HbsAg) positive at the time of entry into the study. at the facility level, assuming a compound symmetry
After initial entry into the study, HBV status was queried covariance structure [34]. For the Cox regression models,
every 4 months. An incident case of HBV infection was the Sandwich Estimator was used to account for cluster-
defined as seroconversion by a patient from HbsAg nega- ing at the facility level [35]. All analyses were performed
tive at the time of entry into the study to HbsAg positive using the SAS statistical package, version 8.2 (SAS Insti-
in the reporting center during the study period. tute, Cary, NC, USA).
Statistical methods
Demographics, comorbidity, and country analysis. The RESULTS
main outcome variables of interest were HBV preva-
The initial sample included 8615 randomly selectedlence and HBV seroconversion rates. Prevalence per-
hemodialysis patients. These patients were treated in 308centages represented a cross-section taken at the begin-
dialysis facilities. Table 1 (column 2) summarizes thening of the study. HBV seroconversion rates were
demographic and comorbid characteristics of the patientcalculated as the number of conversions per 100 patient-
sample. The mean and the median ages were 59.9 yearsyears of observation. Independent variables included
and 62.0 years, respectively. African American patientscountry, patient demographics (age, gender, and race),
comprised 17.4% of the sample and males 56.8%; 42%time on hemodialysis, alcohol or drug use in the past 12
of the patients were over 65 years old. Two potentialmonths, and history of the following comorbid condi-
risk factors for HBV, drug and alcohol abuse, were notedtions: hepatitis C infection (HCV), prior renal transplant,
coronary artery disease, congestive heart failure (CHF), in 3.0% and 1.7% of the sample, respectively.
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Table 1. Odds ratios (OR) for prevalence and risk ratio (RR) of seroconversion of hepatitis B (HBV) by patient characteristicsa
Patients (%) or OR for prevalence Risk ratio for seroconversion
Measure mean (SD) (P value) (P value)
Ageb 59.9 (14.7) 0.90 (0.03) 1.09 (0.28)
Race
Non-African American 82.6 1.00 (ref) 1.00 (ref)
African American 17.4 1.28 (0.20) 1.26 (0.57)
Gender
Male 56.8 1.41 (0.003) 0.92 (0.66)
Female 43.2 1.00 (ref) 1.00 (ref)
Time on ESRD 4.9 (5.4) 1.04 (0.04) 1.00 (0.99)
Comorbid conditions
HCV 15.9 2.74 (0.0001) 1.71 (0.03)
Prior Renal Transplant 6.8 1.09 (0.69) 0.73 (0.57)
PVD 21.3 0.77 (0.05) 0.51 (0.07)
HIV/AIDS 0.5 3.74 (0.0003) 2.66 (0.36)
Psychiatric disease 18.9 1.01 (0.96) 1.85 (0.05)
Dyspnea 19.8 0.72 (0.04) 1.13 (0.72)
CAD 36.0 1.20 (0.19) 0.86 (0.53)
CHF 29.6 1.03 (0.85) 0.85 (0.62)
Arrhythmia/other cardiac disease 33.2 1.27 (0.05) 0.78 (0.40)
HTN 73.2 1.07 (0.64) 1.06 (0.78)
Cerebrovascular disease 15.5 1.05 (0.76) 0.59 (0.08)
Diabetes 33.0 1.14 (0.34) 1.53 (0.09)
Lung disease 9.4 0.80 (0.23) 0.63 (0.47)
Cancer 8.3 1.12 (0.54) 0.82 (0.65)
Gastrointestinal bleeding 6.9 1.26 (0.24) 0.94 (0.91)
Neurologic disease 8.4 0.92 (0.65) 1.72 (0.13)
Recurrent cellulitis/gangrene 7.5 0.80 (0.38) 1.10 (0.87)
Substance abuse within past 12 months
Drug 3.0 0.90 (0.74) 0.24 (0.18)
Alcohol 1.7 1.32 (0.36) 1.35 (0.58)
Abbreviations are: ESRD, end-stage renal disease; HCV, hepatitis C virus; PVD, peripheral vascular disease; HIV/AIDS, human immunodeficiency virus/acquired
immunodeficiency disease; CAD, coronary artery disease; CHF, congestive heart failure; HTN, hypertension.
a Adjusted for age, gender, race, time on dialysis, alcohol use and drug abuse in the past 12 months, 15 comorbid conditions, and clustering effects
b OR and RR are given for increments of 10 years
HBV prevalence lence was 10% lower per 10 years older age (P  0.03).
Male gender was associated with a 41% higher risk forAnswers to the question “History of HBV?” were com-
prevalence of HBV. Infection with HCV was stronglybined with serology results to define HBV classification.
and significantly associated with HBV prevalence [ad-For 8433 out of 8615 patients (97.9%), the combination
justed odds ratio (AOR)  2.74, P  0.0001]. HBV wasof answers gave a clear and unambiguous HBV classifica-
significantly less prevalent in those patients with PVDtion of either HBV positive of HBV negative. For 107
(AOR 0.77, P 0.05) and significantly more prevalentpatients, the question “History of HBV?” was answered
in those patients with HIV/AIDS (AOR  3.74, P “yes” and the patient was HbsAg negative. As HbsAg
0.0003). Substance abuse as reported by the patient dur-may disappear with convalescence, these patients were
ing the 12 months prior to data collection was not signifi-classified as HBV positive. There were 15 patients for
cantly associated with HBV prevalence.whom “History of HBV?” was answered “suspected.”
Table 2 provides HBV prevalence percentages byFor two of these patients HbsAb was positive, and the
country, after adjustment for age, gender, race, and timepatients were classified HBV positive. For 12 of these
of ESRD. Adjusted HBV prevalence was higher inpatients HbsAg was negative, and the patients were clas-
France, Germany, and Italy, and lower in Japan, Spain,sified HBV negative. For the remaining sole patient with
and the United Kingdom.a suspected history of HBV, HbsAg was unknown, and
The pattern of prevalence of HBV by interval of timethe patient was classified HBV positive. Sixty patients
of ESRD is shown in Figure 1. Prevalence of HBV waswere missing both a response to “History of hepatitis B?”
lowest among patients who had been treated with hemo-and missing the HbsAg serology. These patients were
dialysis for 0 to 5 years and then increased as years sinceexcluded from the analysis.
onset of ESRD increased. Time on ESRD therapy wasTable 1 (column 3) provides the odds ratio (OR) for
significantly associated with HBV prevalence, with a 4%HBV prevalence, as predicted by the demographic and
higher odds ratio of HBV prevalence per year of ESRDcomorbid characteristics of the sample. Younger age was
significantly associated with prior HBV infection. Preva- (Table 1) (AOR  1.04, P  0.04).
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Table 2. Prevalence and seroconversion rates, by countrya
Unadjusted Adjusted prevalencea Unadjusted seroconversions/ Adjusted seroconversions/
Country prevalence % %, 95% CI 100 patient-years 100 patient-yearsa 95% CI
France 5.0 (3.2, 6.8) 3.7 (2.9, 4.7) 0.9 (0.6, 1.4) 1.0 (0.4, 3.1)
Germany 5.2 (3.3, 7.1) 4.6 (3.6, 5.8) 1.1 (0.9, 1.3) 1.8 (0.6, 4.9)
Italy 6.6 (4.5, 8.7) 4.3 (3.4, 5.4) 0.5 (0.3, 0.9) 0.5 (0.1, 1.6)
Japan 3.3 (2.5, 4.1) 2.1 (1.6, 2.6) 1.2 (1.0, 1.4) 1.0 (0.4, 2.8)
Spain 3.1 (1.6, 4.6) 2.1 (1.6, 2.7) 0.7 (0.4, 1.1) 0.7 (0.2, 2.1)
United Kingdom 0.0 (—, —) 0.0 (—, —) 0.4 (0.1, 1.1) 0.5 (0.1, 2.3)
United States 2.8 (2.3, 3.3) 2.4 (2.1, 2.7) 0.4 (0.3, 0.5) 0.4 (0.2, 0.6)
Overall 3.3 — 0.7 —
a Adjusted for age, gender, race, time on dialysis, hepatitis C virus (HCV), previous transplantation, alcohol use, and drug abuse in the past 12 months
Fig. 1. Variation in hepatitis B virus (HBV) prevalence by patient’s
time on dialysis. The mean time on ESRD was 4.9 years, with a SD of
5.4 years.
Fig. 2. Distribution of hepatitis B virus (HBV) prevalence by facility.
Mean HBV prevalence was 3.1%, with a median of 2.0%. The percent-
age of facilities with an HBV prevalence of 0% to 5% was 77%.
Figure 2 shows the distribution of HBV prevalence
across dialysis facilities. In the 308 facilities studied, the
mean HBV prevalence was 3.1% with a median of 2.0%. justed HBV seroconversion rates ranged from 0.4 to 1.8
The majority of facilities (78.5%) had HBV prevalence seroconversions/100 patient-years.
between 0% and 5%. Only 6.8% of facilities had HBV Figure 3 shows the facility distribution of HBV sero-
prevalence greater than 10%. conversion rates. Overall HBV seroconversion rate was
0.78 events per 100 patient-years. The majority of facili-
HBV seroconversion ties (78.1%) had a seroconversion rate of 0 conversions
Table 1 (column 4) provides the risk ratio (RR) of per 100 patient-years.
HBV seroconversion for a variety of demographic char-
Practice patterns and facility characteristicsacteristics and comorbid conditions. Seroconversion was
not significantly associated with any of the following Several practice patterns were evaluated for their asso-
factors: age, African American race, male gender, or ciation with HBV prevalence and seroconversion, as
time of ESRD by year. Infection with HCV was strongly shown in Table 3. Results are shown for separate models
and significantly associated with higher risk of seroconv- (each practice pattern modeled separately) and com-
ersion (AOR  1.71, P  0.03). Substance abuse as bined models (all practice patterns included in the model
reported by the patient during the 12 months prior to simultaneously). All models were adjusted for patient
data collection was not significantly associated with HBV characteristics. One practice pattern was significantly as-
seroconversion. sociated with HBV prevalence in the models with a single
Table 2 provides HBV seroconversion rates by coun- practice pattern. HBV prevalence was higher in facilities
try, after adjustment for age, gender, race, time on dial- with an increase in the ratio of patients to dialysis stations
(OR  1.09, P  0.03). There was also an associationysis, and 10 facility practice patterns. The RR for ad-
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Table 3. Associations among practice patterns and outcomesa
Prevalence OR Seroconversion RRb
Separate model Combined model Separate model Combined model
Practice pattern (P value) (P value) (P value) (P value)
Protocol for hepatitis B virus-infected patients yes/no 1.20 (0.46) 1.16 (0.53) 0.52 (0.03)c 0.44 (0.01)c
Isolate hepatitis B virus patients % 1.51 (0.06) 1.58 (0.047)c 0.77 (0.41) 0.78 (0.52)
Isolate hepatitis C virus patients % 1.20 (0.48) 0.82 (0.52) 0.60 (0.28) 0.53 (0.29)
Number of isolation stations per station 1.06 (0.22) 1.02 (0.71) 0.96 (0.56) 1.00 (0.98)
Patients/station per 1 unit increase 1.09 (0.03)c 1.11 (0.01)c 0.96 (0.56) 0.91 (0.28)
Hepatitis B virus vaccine routinely administered yes/no 0.71 (0.09) 0.80 (0.30) 2.58 (0.02)c 11.2 (0.007)d
Highly trained staff e per 10%f 0.92 (0.13) 0.91 (0.12) 1.41 (0.73) 1.03 (0.70)
Physician patient interaction min/month 1.00 (0.27) 1.00 (0.31) 1.00 (0.46) 1.00 (0.26)
Patient hours/direct patient staff hours 0.94 (0.69) 0.94 (0.70) 0.91 (0.54) 0.92 (0.63)
Routine screening for hepatitis B virus yes/no 1.33 (0.32) 1.44 (0.23) 1.01 (0.97) 0.76 (0.45)
Routine screening for hepatitis C virus yes/no 0.93 (0.71) 0.83 (0.30) 1.19 (0.55) 1.14 (0.71)
Facility treats acute patients yes/no 1.24 (0.24) 1.26 (0.26) 1.04 (0.90) 1.07 (0.83)
Facility size per 10 patients 1.01 (0.23) 1.00 (0.99) 0.99 (0.53) 0.99 (0.71)
Dialyzer reuseg 0.74 (0.19) 0.74 (0.52) 1.15 (0.74) 1.06 (0.91)
a Adjusted for age, gender, race, time on dialysis, comorbid conditions, history of drug use, history of alcohol use, presence of hepatitis C virus at the patient level,
history of renal transplantation, hospital-based facility, and country of residence
b Also adjusted for facility prevalence of HBV
c P  0.05
d P  0.01
e Highly trained staff is defined as at least 2 years of formal nursing training
f For freestanding units only
g Model included only the three countries in DOPPS that reuse: the United States, Spain, and the United Kingdom
administration of HBV vaccine (RR  2.58, P  0.02).
Both of these practice patterns retained significance in
the models that included all practice patterns: protocol
for HBV-infected patients (RR  0.44, P  0.01), and
routine administration of HBV vaccine (RR 11.2, P
0.007). Dialyzer reuse was not significantly associated
with HBV seroconversion.
DISCUSSION
This prospective study estimated HBV prevalence and
seroconversion rates in hemodialysis units in seven coun-
tries and evaluated associations between facility level
practice patterns and HBV prevalence and seroconver-
sion. The observed results indicate that HBV persisted
even in the current environment of infection control
measures. Furthermore, this analysis of DOPPS dataFig. 3. Distribution of hepatitis B virus (HBV) seroconversion rates
by facility. In 78.1% of facilities, the mean seroconversion rate was 0 demonstrates variation in HBV outcomes by patient
seroconversions per 100 patient-years. characteristics (Table 1), by country (Table 2), and by
hemodialysis facility practice patterns (Table 3). The
DOPPS estimates of HBV prevalence by country do not
contradict published reports that prevalence of HBVbetween increased HBV prevalence and isolation of pa-
among hemodialysis patients is relatively higher in Italytients infected with HBV (OR  1.51, P  0.06). Two
and lower in Japan [26, 27]. It is possible that the differ-practice patterns were significant in the model that in-
ences we observed reflect differences in the underlyingcluded all practice patterns: isolating HBV patients (OR
prevalence rate of HBV infection in the general popula-1.58, P  0.047), and ratio of patients per station, with
tion in these countries. Selection of patients to alterna-an AOR of 1.11 for each additional patient dialyzing at
tive renal replacement therapies is also possible. Thea hemodialysis station (P  0.01).
United Kingdom treats a greater proportion of chronicIn the models for HBV seroconversion that examined
dialysis patients with peritoneal dialysis. It is possiblea single practice pattern, two practice patterns reached
that patients in the United Kingdom with prior HBVa level of significance: presence of a protocol for HBV-
infected patients (RR  0.52, P  0.03) and routine infection are preferentially treated by peritoneal dialysis.
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The DOPPS study did not evaluate HBV prevalence cific clinical routines related to handwashing, use of
and seroconversion in developing countries, where stud- gloves, or placement of patients and machines that mini-
ies have shown HBV infection rates are much higher mized the spread of HBV. It is likely that further defini-
[29–32]. tion of optimal practice patterns and protocols at the
The positive association between HBV prevalence and facility level will yield opportunities for improved HBV
years on hemodialysis (Fig. 1) has been found previously. control.
Albertoni et al [10] reported a sharp increase in HbsAg A key component of past and present infection control
carriers in patients with 10 years or more of hemodialysis, protocols is segregation of HbsAg-positive patients and
a finding they attributed to a cohort effect. Our study, their equipment. In this study, practice patterns related
using data from 1997 through 1999, finds evidence for a to patient isolation were linked with HBV prevalence
cohort effect during a similar time period. DOPPS data and seroconversion (Table 3). The association between
demonstrate a markedly higher HBV prevalence in pa- isolation of patients infected with HBV and increased
tients with 18 years or more of hemodialysis. The positive prevalence of HBV may indicate the response of hemo-
association between HBV prevalence and years of hemo- dialysis units to a higher HBV prevalence in their dialysis
dialysis has several possible explanations. Older patients population. Dialysis centers with a high prevalence of
on dialysis started treatment before routine implementa- HBV may have been more likely to have had a protocol
tion of such practice patterns as donor blood screens that included isolation of patients infected with HBV.
for HbsAg, vaccination of ESRD patients against HBV, Success of such protocols may be reflected in the 22%
universal precautions, and use of erythropoietin. Al- decreased RR for seroconversion associated with isola-
though less likely, it is possible that patients who have tion of patients infected with HBV, although this result
undergone hemodialysis for a longer period of time have did not achieve significance.
a longer time at risk for exposure to HBV than those This analysis found an association between RR for
patients who have been on hemodialysis for a shorter HBV seroconversion and routine administration of HBV
amount of time. vaccine in both the univariate and the multivariate mod-
The significantly decreased risk for seroconversion as- els. The reason for increased RR for HBV seroconver-
sociated with facilities reporting a protocol for patients sion associated with routine administration of HBV vac-
infected with HBV is one of the strongest findings of cine is not clear. Recent outbreaks of HBV have been
this analysis (Table 3). Use of a protocol for control linked to several practice patterns, including failure to
of HBV infection has proven crucial. The first reports of routinely screen patients for HbsAg [39]. Currently, the
success in limiting HBV infection were from the United CDC recommends routine HBV screening and vaccina-
Kingdom after a “prevention and control program” was
tion [38]. One explanation for the association between
started in hemodialysis units in 1970 [36]. Also in 1970,
vaccine administration and RR for seroconversion is thatin response to an outbreak of hepatitis in Edinburgh,
those units with a high rate of new HBV infection areScotland, physicians initiated a specific set of infection
more likely to vaccinate their patients in an effort tocontrol measures that effectively ended the outbreak
control HBV spread than units with a lower rate of new[37]. In 1977, the Centers for Disease Control and Pre-
HBV infection.vention (CDC) in the United States issued a set of recom-
This analysis evaluated associations between staffingmendations for control of HBV in hemodialysis units
practice patterns at the hemodialysis facility level and[22]. The original recommendations were effective and
HBV outcomes. No clear association was found betweenmost are still in place [38].
physician interaction time with hemodialysis patients perHowever, even in the current environment, in which
month and HBV prevalence or seroconversion. Once aninfection control protocols have been established for
infection protocol is in place, it is largely the day-to-over a decade, our analysis found large and significant
day responsibility of the nurses and technicians at thedifferences in HBV outcomes associated with facility-
hemodialysis facility to carry out that protocol. Applica-level practice patterns. In this study, units that identified
tion of the protocol would then be independent of thethemselves as having a protocol for HBV-infected pa-
presence of a physician at the hemodialysis facility. Thetients had a strongly and significantly decreased associa-
decrease in HBV prevalence and seroconversion associ-tion with HBV seroconversion. This striking finding sug-
ated with an increase in the ratio of patient hours togests that facility-level practice patterns related to HBV
direct patient staff hours was both small and not signifi-outcomes still exist, over and above those recommended
cant. The only practice pattern related to staffing thatby the CDC and other country-specific infection control
approached statististical significance in this analysis wasagencies. Limitations of data collection did not allow for
a decreased risk for HBV prevalence in free-standingmore detailed investigation of facility-specific protocols
hemodialysis units with an increased number of highlyfor HBV-infected patients. Those units that identified
themselves as having such a protocol may have had spe- trained staff (at least 2 years of formal nursing training).
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